Day Two 

Thursday November 21, 2024

08:30am Limited Places Available: Exclusive Breakfast Briefing, Considering Portfolio Strategy When Scaling Up Your Small/Mid-Sized Biotech

  • Wendy Cheung Vice President - Pipeline Commercialization & Strategy Oncology, Abbvie
  • Nina Aragam Vice President, Portfolio Strategy and Program Management, Replimune

10:30am End of Breakfast Briefing

09:30am Conference Day Two Welcome Coffee

10:50am Chair’s Opening Remarks

Harnessing Technological Advancements in Strategic Decision-Making Processes

11:00am Fireside Chat: Strategic Integration: Balancing Human Expertise and Artificial Intelligence in Digital Transformation

  • Richard Van Healthcare Innovation & Strategy Lead, US Immunology, UCB
  • David Yee Head, Portfolio Systems, Novartis AG

Synopsis

  • Overview of how AI is currently being utilized in biopharma
  • Greatest opportunities for AI to enhance biopharma operations and decision-making processes
  • Challenges and limitations associated with integrating AI into biopharma operations
  • Ethical considerations surrounding AI adoption
  • Exploring the optimal balance between human expertise and AI capabilities in decision-making processes Future trends in AI technology and their potential impact on biopharma

Leveraging Data Analytics for Data-Driven Decision Making in Portfolio Strategics

11:45am Architecture for Structured Decision-Making

  • Craig Ulmer Senior Director - Global Program Management & Neuroscience, Takeda Pharmaceutical Co. Ltd.

Synopsis

  • Understand how pharmaceutical and biotech PPMs can utilize a structured architectural framework to enhance decision-making processes
  • Explore how analytics and data-driven approaches can increase the Probability of Technical Success (PTS) and provide informed options for timeline, scope, and budget scenarios
  • Learn how integrating these methods into drug development plans leads to better project and portfolio outcomes.

12:15am Networking Break

12:45am Getting the Right Data: Ensuring Current, Reliable, & Complete Data for Informed Decision-Making in Pharma

  • Richard Van Healthcare Innovation & Strategy Lead, US Immunology, UCB

Synopsis

  • Implementing robust processes to guarantee that data inputs are current, reliable, and complete for informed decision making
  • Strategies to overcome internal biases and ensure data accuracy, addressing
  • Techniques for effectively communicating data insights to senior management, ensuring that the information is well-understood and actionable

1:15pm Standardizing Data Acquisition and Utilization Across Diverse Business Units

  • David Yee Head, Portfolio Systems, Novartis AG

Synopsis

  • Ensuring a seamless flow of information throughout the organization
  • Implementing master data management practices to optimize data operations, governance, and stewardship for quicker, cleaner, and standardized data access
  • Ensuring rapid, clean, and standardized data delivery to enable swift and effective decision-making, enhancing overall organizational efficiency

1:45pm Lunch & Networking

Optimizing the Approach to Strategic External Collaborations & Partnerships

2:15pm Innovative Collaborations: Exploring Non-Classical Partnerships Between Foundations and Pharma

  • Douglas Macdonald Director - Research Operations & Scientific Alliances, CHDI Management Inc.

Synopsis

  • Diverse contributions that foundations bring to partnerships with pharmaceutical companies, including disease domain knowledge, research tools, funding support, stakeholder engagement, and advocacy for patient groups
  • Examining various operational models used in non-classical partnerships employing various levels of engagement, such as research enablement, collaborative research, and contract-based funding to advance medical innovation
  • Analyzing the impact of these partnerships on accelerating research and development efforts, enhancing innovation in drug discovery and biomarkers, and overcoming barriers in disease specific research

Navigating Biopharma’s Dynamic Challenges of Commercial Viability

2:45pm Roundtable Discussion: Determining Commercial Viability of Assets in Dynamic Market Conditions

Synopsis

Market changes underscore the complexity and dynamic nature of the pharmaceutical industry, requiring companies to adapt swiftly and strategically to maintain commercial viability and capitalize on emerging opportunities.

Discuss with peers the challenges, implications and opportunities associated with:

  • Shifting economic factors like the Inflation Reduction Act
  • Evolving healthcare reforms affecting Medicare Reimbursement Rates
  • Competitive impact of new entrants, generics or biosimilars

3:15pm Chair’s Closing Remarks

3:30pm End of Day Two